media – Page 623 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Psychedelics and Psychotherapy–Is There a Role for MDMA in the Treatment of PTSD?

In a recent study, scientists investigate the use of MDMA in conjunction with psychotherapy as an aid in treating and alleviating PTSD symptoms.
- Source: medicalnewsbulletin
- 477
- November 20, 2017
psychotherapy PTSD symptom Researches
Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck

Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada.
- Source: biotech-365
- 540
- November 20, 2017
autoimmune immunotherapy Market Views
FDA approves new treatment Hemlibra (emicizumab-kxwh) to prevent bleeding in certain patients with hemophilia A

The U.S. Food and Drug Administration(FDA) approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.
- Source: pharmacist
- 756
- November 20, 2017
FDA Hemlibra hemophilia inhibitor New Approvals
Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients

Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration(FDA) has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). The approval was based on results from the S-TRAC trial that demonstrated a significant reduction in the risk of a disease-free survival (DFS) event (defined as the interval between randomization and tumor recurrence, or secondary primary cancer or death from any cause) for patients at high risk of RCC recurrence who received SUTENT compared to placebo in the adjuvant setting.
- Source: finance.yahoo
- 504
- November 20, 2017
DFS FDA nephrectomy RCC SUTENT
Like a baby– The vicious cycle of childhood obesity and snoring

Poor nutrition and lack of exercise lead to the increasing prevalence of obesity which, in turn, is the major predictor of diabetes and future risk of cardiovascular disease in western societies. v
- Source: medicalxpress
- 550
- November 20, 2017
cardiovascular disease diabetes obesity obstructive sleep apnea
What if clients ask me to send samples?

Sending samples may not sound like be a big deal for most people engaged in the medical trade but do you really know how to do it correctly? Today, Ddu will share our tips on effective sample delivery.
- Source: Ddu
- 652
- November 17, 2017
Ddu College sample delivery
Ddu College-China’s Import and Export Market Report of Respiratory System Drugs

Respiratory system drugs is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will share China’s Import and Export Market Report of Respiratory System Drugs with you.
- Source: Ddu
- 1,324
- November 17, 2017
asthma COPD Ddu College pneumonia respiratory
Clinical trial shows treatment is ‘transformative’ for babies with spinal muscular atrophy

Infants with the most severe form of spinal muscular atrophy (SMA) were more likely to show gains in motor function and were 47 percent more likely to survive without permanent assisted ventilation support when treated with a new medication, according to a study published today in the New England Journal of Medicine. The drug, nusinersen, performed so well that the study was stopped early and the treatment was approved shortly thereafter by the U.S. Food and Drug Administration (FDA) for all patients with this progressive neuromuscular disorder.
- Source: sciencedaily
- 462
- November 17, 2017
Market Views neuromuscular disorder SMA
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation

Celgene Corporation and bluebird bio, Inc. announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
- Source: ansa.it
- 598
- November 17, 2017
BTD CAR-T therapy Company Insight
Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Sangamo Therapeutics, Inc. (SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
- Source: finance.yahoo
- 423
- November 17, 2017
Company Insight Hunter syndrome MPS II

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.